vesicular
stomat
viru
vsv
promis
vector
vaccin
oncolysi
also
produc
acut
diseas
cattl
hors
swine
character
vesicul
ulcer
tongu
oral
tissu
feet
teat
experiment
anim
primat
rat
mice
vsv
shown
lead
neurotox
hind
limb
paralysi
viru
matrix
protein
glycoprotein
g
major
pathogen
determin
wildtyp
vsv
major
target
product
attenu
strain
exist
strategi
attenu
includ
delet
substitut
protein
vsv
respect
truncat
cterminu
g
protein
g
despit
mutat
recombin
vsv
mutat
protein
moder
attenu
anim
wherea
detail
report
determin
pathogen
recombin
vsv
truncat
g
protein
high
dose
thu
novel
recombin
vsv
vsv
well
attenu
vsv
vsv
vsvg
produc
determin
efficaci
vaccin
vector
low
pathogen
vitro
studi
indic
truncat
g
protein
g
could
play
import
role
delet
attenu
recombin
vsv
vsv
determin
attenu
viru
low
pathogen
mice
vsvg
also
show
rel
reduc
pathogen
neutral
antibodi
stimul
vsvg
prove
significantli
higher
mice
treat
vsv
conclus
among
differ
attenu
vsv
mutat
andor
g
protein
recombin
vsv
truncat
g
protein
vsvg
demonstr
ideal
balanc
pathogenesi
stimul
protect
immun
respons
properti
make
vsvg
promis
vaccin
vector
vaccin
candid
prevent
vesicular
stomat
diseas
vesicular
stomat
viru
vsv
singlestrain
negativesens
rna
viru
wide
use
vector
vaccin
develop
recombin
vsv
accommod
larg
multipl
foreign
gene
genom
express
high
level
confer
advantag
rna
viral
vector
due
potent
capabl
trigger
cellular
humor
mucos
immun
anim
even
singl
administr
recombin
vsv
studi
vaccin
vector
prevent
vesicular
stomat
diseas
livestock
number
human
pathogen
includ
influenza
viru
ebola
viru
marburg
viru
human
immunodefici
hiv
viru
sever
acut
respiratori
syndrom
sar
viru
hepat
c
viru
howev
vsv
notori
infecti
agent
produc
acut
diseas
vesicular
lesion
cattl
swine
hors
neurotox
experiment
anim
includ
primat
mice
therefor
modif
need
improv
safeti
vsv
appli
clinic
replic
compet
vector
vsv
genom
rna
transcrib
five
cap
polyadenyl
mrna
viral
rnadepend
rna
polymeras
mrna
encod
five
structur
protein
nucleocapsid
protein
n
phosphoprotein
p
cofactor
rnadepend
rna
polymeras
l
matrix
protein
attach
glycoprotein
g
g
protein
primari
pathogen
determin
vsv
protein
multifunct
protein
involv
viru
assembl
bud
pathogenesi
capabl
inhibit
transport
host
mrna
nucleu
significantli
inhibit
type
interferon
ifn
signal
g
protein
respons
viral
bind
host
receptor
entri
vsv
host
cell
cytoplasm
domain
see
front
matter
elsevi
ltd
right
reserv
consid
play
import
role
viral
bud
packag
date
sever
strategi
focus
g
protein
gener
attenu
vsv
report
delet
methionin
residu
vsv
substitut
within
protein
lead
attenu
due
potent
induct
type
ifn
anoth
attenu
strategi
depend
upon
truncat
within
ctermin
region
g
protein
vsvg
significantli
impact
viral
bud
packag
effici
vivo
howev
vsv
protein
mutant
prove
moder
attenu
experiment
infect
wherea
current
inform
avail
recombin
vsv
truncat
g
protein
safe
anim
challeng
high
dose
mutant
viru
current
studi
develop
novel
recombin
vsv
vsv
mutat
g
protein
includ
delet
methionin
protein
truncat
amino
acid
ctermin
region
g
protein
hypothes
vsv
could
combin
advantag
observ
g
mutat
produc
safer
effect
vaccin
vector
furthermor
first
time
differ
attenu
vsv
mutat
andor
g
protein
comprehens
compar
vitro
vivo
base
pathogen
capabl
stimul
potent
immun
respons
aim
identifi
suitabl
recombin
vsv
vaccin
vector
vaccin
candid
prevent
vesicular
stomat
diseas
recombin
vsv
rescu
studi
base
infecti
clone
vsv
indiana
plasmid
pvsv
kindli
provid
prof
john
bell
univ
ottawa
canada
pvsv
helper
plasmid
pbsn
p
l
provid
prof
glen
barber
lab
univ
miami
usa
pvsvg
pvsv
construct
base
pvsv
pvsv
respect
construct
wildtyp
vsv
g
protein
cytoplasm
tail
aa
truncat
one
arginin
residu
remain
tail
g
fig
forward
primer
use
polymeras
chain
reaction
pcr
amplif
g
underlin
indic
mlui
restrict
site
revers
primer
underlin
indic
xhoi
restrict
site
bold
residu
indic
two
tandem
repeat
stop
codon
construct
pvsvg
pvsv
vsv
g
gene
pvsv
pvsv
substitut
g
restrict
digest
mlui
xhoi
startstop
signal
viral
gene
transcript
preserv
schemat
represent
pvsv
shown
fig
recoveri
recombin
vsv
infecti
clone
perform
previous
describ
briefli
cotransfect
vsv
construct
pvsv
pvsvg
pvsv
helper
plasmid
pbsn
p
l
perform
cell
infect
recombin
vaccinia
viru
express
rna
polymeras
h
posttransfect
cultur
supernat
collect
filter
filter
fresh
cell
cell
check
daili
typic
cytopath
effect
cpe
observ
day
vsv
infect
supernat
collect
virus
plaquepurifi
vero
cell
individu
plaqu
isol
seed
stock
amplifi
cell
recombin
virus
concentr
ultracentrifug
rpmmin
h
frozen
c
viral
titer
determin
plaqu
assay
perform
vero
cell
vsv
wildtyp
g
wt
g
protein
prepar
stock
kept
laboratori
identifi
rescu
recombin
vsv
western
blot
use
identifi
typic
band
l
g
np
protein
use
specif
convalesc
sera
vsv
infect
mice
short
confluent
cell
infect
vsv
vsv
g
vsv
multipl
infect
moi
vsv
use
control
h
postinfect
pi
cell
lyse
buffer
contain
sodium
dodecyl
sulfat
sd
protein
separ
sd
polyacrylamid
gel
electrophoresi
page
transfer
polyvinyliden
fluorid
pvdf
membran
thermo
scientif
rockford
il
usa
mini
transblot
electrophoret
transfer
cell
biorad
hercul
ca
usa
sera
vsv
infect
mous
use
primari
antibodi
dilut
horseradish
peroxidaseconjug
goat
antimous
igg
secondari
antibodi
dilut
santa
cruz
ca
usa
target
band
observ
use
west
pico
chemiluminesc
substrat
thermo
scientif
expos
kodak
biomax
mr
film
kodak
rochest
ny
usa
attenu
viru
could
character
analyz
plaqu
format
size
cell
cell
line
use
type
ifn
signal
compet
cell
line
wherea
vero
cell
use
incompet
cell
line
plaqu
format
experi
set
cell
identifi
role
type
ifn
viral
attenu
briefli
confluent
vero
cell
plate
infect
optim
dilut
vsv
vsv
vsv
g
vsv
cover
low
melt
temperatur
agar
invitrogen
carlsbad
ca
usa
rins
phosphat
buffer
salin
pb
h
pi
crystal
violet
use
stain
vero
cell
wherea
cell
stain
h
pi
plaqu
first
scan
gel
imag
tanon
shanghai
china
bright
light
individu
plaqu
view
photograph
magnif
use
microscop
nikon
tokyo
japan
equip
digit
camera
mean
plaqu
size
determin
measur
area
plaqu
group
use
nikon
nisel
br
softwar
nikon
human
prostat
cancer
cell
line
use
anoth
cell
line
compet
type
ifn
signal
confluenc
cell
plate
infect
virus
low
moi
h
absorpt
inoculum
remov
cell
wash
three
time
pb
fresh
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
ad
infect
cell
incub
c
aliquot
cell
cultur
supernat
remov
h
pi
viral
titer
supernat
detect
plaqu
assay
vero
cell
harvest
h
pi
also
assay
level
use
human
elisa
kit
r
system
minneapoli
mn
usa
specif
pathogen
free
spf
femal
balbc
mice
g
bodi
weight
purchas
shanghai
slac
experiment
anim
compani
chines
academi
scienc
china
divid
five
group
per
group
inocul
intranas
vsv
vsvg
vsv
vsv
pb
light
anesthesia
ketaminexylazin
inocul
dose
differ
vsv
plaqueform
unit
pfu
l
pb
highest
dose
could
prepar
ultracentrifug
vsvg
vsv
anim
bodi
weight
loss
surviv
monitor
everi
day
day
pi
anim
studi
perform
accord
protocol
approv
shanghai
jiaotong
univers
experiment
anim
center
sinc
wildtyp
vsv
possess
neurotrop
could
lead
seriou
neurotox
anim
recoveri
vsv
brain
tissu
perform
identifi
associ
pathogenesi
viral
replic
host
short
spf
mice
divid
five
group
challeng
intranas
vsv
vsv
vsvg
vsv
dose
pfu
control
group
pb
group
two
mice
sacrif
day
postinocul
brain
remov
viral
detect
tissu
weigh
ml
cell
frozen
vial
quickli
frozen
liquid
nitrogen
kept
c
viral
assay
tissu
thaw
suspend
ml
pb
complet
homogen
use
dounc
homogen
homogen
tissu
centrifug
rpm
min
suspens
serial
dilut
pb
viral
titer
determin
standard
plaqu
assay
vero
cell
describ
plaqu
observ
count
h
incub
immun
respons
induc
vsv
vsvg
evalu
balbc
mice
g
femal
spf
balbc
mice
divid
three
group
immun
vsv
vsvg
pb
control
anim
vsv
vsvg
treat
group
divid
two
subgroup
five
per
subgroup
hous
isol
hutch
intranas
inocul
virus
dose
pfu
pfu
l
pb
blood
collect
anesthet
mice
retroorbit
bleed
day
vaccin
vaccin
mice
challeng
vsv
blood
allow
clot
room
temperatur
sera
collect
centrifug
store
c
neutral
assay
sera
anim
heat
inactiv
c
min
vsv
vaccin
anim
serial
dilut
twofold
dmem
start
determin
neutral
antibodi
titer
l
dilut
sera
mix
pfu
vsv
l
dmem
mixtur
incub
h
c
ad
confluent
cell
cell
incub
c
least
day
check
cpe
addit
l
sera
pb
treat
anim
directli
combin
l
vsv
treat
sera
titer
determin
reciproc
dilut
give
inhibit
cpe
record
day
immun
mice
intranas
administ
pfu
vsv
l
pb
anim
observ
everi
day
calcul
surviv
curv
bodi
weight
loss
previous
describ
plaqu
area
concentr
bodi
weight
loss
among
differ
group
compar
student
ttest
twotail
distribut
use
statist
featur
microsoft
excel
microsoft
redmond
wa
usa
virus
rescu
current
studi
base
vsv
indiana
infecti
clone
construct
safer
recombin
vsv
vsv
success
gener
first
time
incorpor
doubl
mutat
g
protein
novel
viru
attenu
vsv
vsv
vsvg
identifi
western
blot
convalesc
serum
mice
infect
vsv
use
wildtyp
vsv
control
band
repres
vsv
structur
protein
identifi
fig
prove
although
length
g
protein
cytoplasm
domain
critic
viral
bud
packag
find
one
arginin
residu
remain
g
protein
cytoplasm
domain
vsv
could
still
rescu
comparison
wildtyp
vsv
g
protein
low
molecular
weight
band
presum
g
detect
fig
viral
rna
differ
recombin
vsv
vsv
vsv
vsvg
extract
reversetranscript
rt
pcr
use
amplifi
viral
g
gene
pcr
product
sequenc
mutat
occur
g
gene
data
shown
two
method
use
assess
attenu
vsv
includ
plaqu
format
size
multicycl
growth
curv
type
ifn
signal
compet
cell
incompet
cell
vero
result
compar
produc
recombin
vsv
crystal
violet
stain
plaqu
size
determin
vero
cell
infect
differ
vsv
fig
vero
cell
averag
plaqu
size
n
vsv
wt
g
vsv
vsv
similar
p
significantli
larger
contain
g
mutat
vsvg
vsv
p
fig
b
averag
plaqu
size
vsvg
vsv
compar
data
indic
type
ifn
signal
incompet
vero
cell
g
involv
vsv
attenu
cell
averag
plaqu
area
produc
vsv
much
larger
vsv
howev
area
vsv
also
larger
vsvg
p
fig
b
smallest
turbid
plaqu
form
vsv
cell
difficult
detect
base
result
g
assist
attenu
vsv
type
ifn
signal
compet
cell
attenu
tendenc
follow
vsv
vsv
vsvg
vsv
also
use
current
studi
type
ifn
signal
compet
cell
line
quantifi
relationship
amount
vsvinduc
type
ifn
viral
replic
titer
multicycl
growth
curv
perform
inocul
virus
low
moi
shown
fig
titer
vsv
reach
highest
level
h
pi
around
pfuml
declin
thereaft
vsv
also
reach
level
vsvtreat
cell
quantifi
h
pi
identifi
role
type
ifn
differ
recombin
vsvinfect
cell
induct
invers
correl
viral
replic
titer
shown
fig
high
level
ifn
induc
vsvtreat
cell
vsv
infect
cell
concentr
reach
pgml
highest
replic
titer
order
magnitud
lower
vsv
although
product
vsv
treat
cell
low
pgml
still
significantli
higher
vsv
p
detect
supernat
vsvg
treat
cell
limit
detect
assay
therefor
viral
attenu
show
follow
trend
vsv
vsv
vsvg
vsv
importantli
fact
led
attenu
vsv
induct
antivir
ifn
prove
studi
base
data
g
shown
involv
attenu
vsv
howev
g
could
play
import
role
regardless
doubl
mutat
vsv
vsv
show
signific
attenu
vitro
current
studi
investig
pathogenesi
vsv
balbc
mice
compar
attenu
vsv
vsv
wildtyp
viru
control
inocul
vsv
intranas
proven
sensit
way
evalu
pathogenesi
vsv
challeng
dose
pfu
wildtyp
vsv
previous
shown
result
signific
mortal
balbc
mice
therefor
studi
spf
balbc
mice
inocul
intranas
differ
recombin
vsv
dose
l
maximum
dose
could
prepar
concentr
vsvg
vsv
l
volum
bodi
weight
surviv
curv
use
indic
pathogenesi
monitor
everi
day
day
pi
shown
fig
bodi
weight
mice
treat
vsv
vsvg
increas
steadili
post
infect
without
death
similar
pb
group
howev
vsv
treat
group
mice
lost
signific
bodi
weight
neurotox
evid
anim
fig
c
anim
die
around
day
pi
fig
vsv
show
moder
attenu
compar
vsv
infect
mice
still
show
signific
loss
bodi
weight
mortal
wildtyp
vsv
possess
neurotrop
mani
anim
includ
primat
rat
mice
lead
seriou
neurolog
deficit
hind
limb
paralysi
identifi
associ
pathogenesi
viral
replic
mice
inocul
intranas
differ
vsv
dose
pfu
virus
isol
brain
anim
screen
plaqu
assay
day
pi
shown
tabl
vsv
treat
mice
show
viral
titer
pfug
day
pi
pfug
day
pi
although
much
lower
vsv
viral
titer
detect
brain
tissu
vsv
infect
mice
determin
pfug
day
pi
viru
detect
day
pi
vsv
vsvg
treat
mice
viru
could
detect
brain
tissu
two
time
point
could
explain
anim
bodi
weight
kept
steadili
increas
durat
studi
group
therefor
studi
show
virul
differ
vsv
close
relat
replic
level
target
organ
name
brain
vsv
safe
truncat
g
protein
vivo
vsv
vsvg
attenu
enough
vaccin
vector
recombin
vsv
truncat
g
protein
vsv
vsvg
prove
significantli
attenu
vitro
vivo
wherea
attenu
viral
vector
often
associ
loss
vector
immunogen
therefor
ideal
viral
vector
retain
essenti
characterist
consid
safe
effect
evalu
protect
immun
stimul
vsv
vsvg
vivo
spf
mice
immun
differ
dose
challeng
lethal
dose
vsv
blood
taken
day
post
immun
neutral
antibodi
assay
shown
fig
vsv
immun
group
immun
pfu
show
surviv
anim
challeng
fig
howev
mice
still
lost
bodi
weight
immun
dose
pfu
anim
die
around
day
postchalleng
anim
suffer
seriou
bodi
weight
loss
recov
slowli
fig
mice
immun
vsvg
dose
pfu
bodi
weight
anim
increas
steadili
challeng
death
signific
bodi
weight
loss
anim
pb
control
group
die
day
postchalleng
fig
therefor
data
suggest
vsvg
could
stimul
potent
protect
immun
vsv
character
protect
respons
neutral
antibodi
develop
vaccin
anim
assay
shown
tabl
antibodi
titer
could
detect
anim
vaccin
pb
treat
mice
determin
antibodi
titer
gener
immun
vsvg
parent
vsv
indiana
significantli
higher
produc
vsv
immun
vsvg
group
antibodi
titer
vaccin
dose
pfu
pfu
howev
vsv
group
dose
pfu
antibodi
titer
mice
titer
die
postchalleng
fig
indic
titer
unabl
protect
anim
moreov
even
anim
vaccin
pfu
antibodi
titer
reach
base
result
could
conclud
vsvg
could
stimul
potent
protect
humor
immun
respons
vsv
might
due
extrem
attenu
vsv
vivo
result
vsvg
may
attain
ideal
balanc
pathogenesi
stimul
protect
immun
respons
potenti
vaccin
vector
vaccin
candid
vesicular
stomat
diseas
replicationcompet
virus
littl
pathogenesi
import
altern
develop
vaccin
vaccin
vector
due
capabl
stimul
potent
comprehens
immun
vivo
howev
safeti
efficaci
equal
import
criteria
tradit
isol
spontan
attenu
viru
host
serial
passag
wildtyp
viru
nonnatur
host
import
method
acquir
attenu
virus
develop
molecular
technolog
construct
recombin
virus
base
revers
genet
becom
common
develop
novel
viral
vector
vsv
promis
vector
vaccin
oncolysi
still
appli
clinic
one
main
reason
lie
potenti
pathogenesi
human
anim
rearrang
structur
protein
gene
mutat
g
protein
exist
strategi
gener
attenu
vsv
replic
compet
studi
focus
two
pathogen
protein
vsv
g
protein
purpos
make
safer
vsv
tabl
recombin
vsv
recov
brain
tissu
mice
pfug
mice
inocul
recombin
vsv
includ
vsv
vsvg
vsv
pb
control
brain
two
mice
remov
day
postinocul
homogen
brain
assay
viral
titer
mean
valu
calcul
nd
detect
viral
titer
mice
brain
pfug
vsv
attenu
vivo
hand
vsv
envelop
viru
releas
via
bud
host
cell
membran
previou
studi
note
length
cytoplasm
domain
vsv
g
specif
sequenc
requir
effici
viral
bud
real
role
truncat
g
protein
attenu
vsv
still
identifi
although
report
vsv
ctermin
truncat
g
protein
acquir
complex
oligosaccharid
slower
wt
g
protein
display
reduc
rate
transport
endoplasm
reticulum
golgi
apparatu
presum
cell
surfac
vitro
assay
type
ifn
signal
compet
cellsincompet
cell
g
proven
import
vsv
attenu
vero
cell
g
involv
vsv
attenu
recombin
vsv
g
shown
form
significantli
smaller
plaqu
viru
wildtyp
g
wherea
plaqu
size
vsv
vsv
vsvg
vsv
similar
matter
whether
protein
mutat
howev
cell
effect
type
ifn
signal
attenu
tendenc
demonstr
follow
tendenc
vsv
vsv
vsvg
vsv
tendenc
also
proven
cell
multicycl
growth
curv
character
replic
titer
differ
vsv
shown
invers
correl
express
level
type
ifn
vsv
form
smallest
plaqu
cell
lowest
titer
cell
among
vsv
test
current
studi
due
doubl
mutat
g
protein
studi
develop
two
main
conclus
vitro
vivo
studi
g
mutat
assist
attenu
vsv
g
could
play
import
role
attenu
therefor
vsv
suitabl
vaccin
vector
due
potenti
pathogenesi
anim
safeti
import
criteria
develop
vaccin
vaccin
vector
hand
vsv
may
suitabl
virotherapi
mani
studi
attempt
sinc
efficaci
prioriti
antitumor
drug
mani
type
tumor
cell
type
ifn
signal
defect
therefor
oncolyt
viru
vsv
could
replic
select
potent
tumor
cell
rare
normal
cell
compet
type
ifn
signal
ideal
replic
compet
vaccin
vector
possess
suitabl
balanc
pathogenesi
capabl
stimul
immun
effect
vsvg
vsv
demonstr
signific
attenu
compar
vsv
vsv
consid
safe
vaccin
vector
howev
sought
determin
attenu
viru
would
work
better
stimul
potent
protect
immun
critic
clinic
applic
evalu
protect
immun
stimul
vsvg
vsv
anim
immun
differ
dose
virus
challeng
lethal
dose
vsv
gold
standard
evalu
efficaci
vsv
vaccin
shown
current
studi
vsvg
could
stimul
potent
protect
immun
vsv
note
vsvg
treat
anim
inocul
low
pfu
dose
death
signific
bodi
weight
loss
observ
postchalleng
vsv
howev
anim
vsv
treat
group
suffer
seriou
bodi
weight
loss
even
immun
pfu
tabl
serum
neutral
antibodi
titer
mice
vsv
indianna
inocul
vsvg
vsv
anim
inocul
pfu
differ
vsv
pb
control
sera
collect
day
inocul
neutral
antibodi
titer
vsv
indiana
determin
express
reciproc
highest
dilut
antibodi
give
inhibit
cytopath
effect
detect
anim
die
dose
low
pfu
result
correl
neutral
antibodi
titer
stimul
differ
vsv
neutral
antibodi
titer
anim
vaccin
vsvg
shown
much
higher
vsv
therefor
although
vsv
contain
doubl
mutat
g
protein
safe
viral
vector
effect
vsvg
stimul
protect
immun
possibl
due
extrem
attenu
vivo
summari
among
differ
attenu
vsv
mutat
orand
g
protein
recombin
vsv
truncat
g
protein
vsvg
indic
ideal
balanc
pathogenesi
capabl
stimul
protect
immun
respons
could
promis
vaccin
vector
howev
purpos
develop
vaccin
candid
prevent
vsv
pandem
vaccin
candid
would
need
evalu
swine
cattl
natur
host
vsv
applic
field
current
studi
novel
recombin
vsv
construct
mutat
g
g
protein
first
time
vsv
mutat
andor
g
protein
vsv
vsvg
vsv
compar
evalu
potenti
vaccin
vector
experiment
conclus
includ
g
contribut
attenu
vsv
howev
g
like
play
import
role
vsv
determin
show
signific
attenu
vitro
virul
recombin
vsv
truncat
g
protein
vsvg
vsv
significantli
decreas
compar
wildtyp
vsv
vsv
vsvg
could
stimul
potent
protect
immun
respons
vsv
possibl
due
extrem
attenu
vsv
among
differ
attenu
vsv
mutat
andor
g
protein
recombin
vsv
truncat
g
protein
vsvg
display
ideal
balanc
pathogenesi
stimul
protect
immun
respons
could
use
promis
vaccin
vector
